Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 studyLihua E. Budde, Nancy L. Bartlett, Laurie H. Sehn et al.|The Lancet Oncology|2022Cited by 429
Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1Maike Janssen, Sascha Dietrich, Christina Schmidt et al.|Blood|2022Cited by 100
Genetic and phenotypic attributes of splenic marginal zone lymphomaFerdinando Bonfiglio, Estella Matutes, Alessio Bruscaggin et al.|Blood|2021Cited by 96
Proteogenomics refines the molecular classification of chronic lymphocytic leukemiaSophie A. Herbst, Sascha Dietrich, Alexander J. Helmboldt et al.|Nature Communications|2022Cited by 42
Integrative multi-omics reveals a regulatory and exhausted T-cell landscape in CLL and identifies galectin-9 as an immunotherapy targetLaura Llaó Cid, Martina Seiffert, Jkl Wong et al.|Nature Communications|2025Cited by 14